Skip to content

Menu

Network Sub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport

Search

Close

Enter Search Terms

Michael Ellenberger

Michael Ellenberger

ID: 1b82610b-2619-30fb-68c4

/

Claimed Record

/

Organization: Rothwell Figg

Much Ado About “About”

Biosimilars Law Bulletin · May 14, 2026

Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update

RF EMerge · March 5, 2026

FDA Proposes Sweeping Changes to Accelerate Biosimilar Development

Biosimilars Law Bulletin · November 7, 2025

Key IP Licensing Considerations for AI Drug Discovery Platforms

RF EMerge · October 17, 2025

Beyond Guinea Pigs: Patent Risks and Opportunities in AI-Enabled Drug Development

Biosimilars Law Bulletin · July 23, 2025

Previous

12 3

Next

Practice Areas

Health Care and Life Sciences

Business and Commercial

Jurisdictions

Washington, D.C.

Publishing Record

Publisher Since 2024

Total Articles 12

Most Recent May 14, 2026

Cite This Author

Michael Ellenberger, Rothwell Figg

LexBlog Author ID:

1b82610b-2619-30fb-68c4

www.lexblog.com/author/mellenberger

Contact

FirmRothwell Figg

Emailmellenberger@rothwellfigg.com

BlogsBiosimilars Law Bulletin

LinkedInView Profile

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS

About LexBlog
The Field We Built
Our Beliefs
Our Team
Contact LexBlog

Disclaimer
Editorial Policy
Terms of Service

Get Started
Publishing Solutions
Compass

Submit a Request
Support Center
System Status

Copyright © 2026, LexBlog, Inc. All Rights Reserved.

Law blog design & platform by LexBlog